Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Merck

The faulty forecasts of pharma firm investors: Misguided cynics miss the promising prognosis for drugmakers Pfizer and Merck

Pfizer and Merck, ostensibly beleaguered drugmakers, have seen their shares battered despite reporting strong earnings.

Fortune

Stock Market Today: Earnings Speak Louder Than Tariffs

Recent market reaction to Trump administration policy announcements has been "entirely normal."

Kiplinger

What Are Wall Street Analysts’ Target Price for Merck Stock?

Merck has considerably underperformed the broader market over the past year, but analysts are highly optimistic about the stock’s prospects.

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

Stock Index Futures Muted Ahead of U.S. JOLTs Report and Fed Speak, Alphabet Earnings on Tap

March S&P 500 E-Mini futures (ESH25) are down -0.01%, and March Nasdaq 100 E-Mini futures (NQH25) are up +0.08% this morning as investors awaited the latest reading on U.S. job openings, comments from Federal Reserve officials, and corporate earnings reports from heavyweight names.

Barchart

Stock Index Futures Slip on Trade War Concerns, U.S. JOLTs Report and Alphabet Earnings on Tap

March S&P 500 E-Mini futures (ESH25) are down -0.21%, and March Nasdaq 100 E-Mini futures (NQH25) are down -0.11% this morning as investors adopted a cautious stance after China retaliated to new U.S. tariffs.

Barchart

Kennedy to divest interest from HPV vaccine lawsuits - Roll Call

President Donald Trump’s Health and Human Services nominee said he will divest his interest in lawsuits against an HPV vaccine manufacturer.

Roll Call

Robert F. Kennedy, Jr. Retains Financial Interest In Vaccine Litigation

Robert F. Kennedy, Jr. faces potential conflicts of interest as HHS secretary nominee due to financial ties with law firms handling litigation against drug...

Top News

Breast cancer drug Lynparza reduces risk of death by 28% in patients diagnosed early, clinical trial shows

About 87.5% of patients treated with the drug were alive after six years, compared to 83.2% who received a placebo.

Fortune

Vaccine misinformation distorts science – a biochemist explains how RFK Jr. and his lawyer’s claims threaten public health

Vaccinations provide significant protection for the public against infectious diseases and substantially reduce health care costs. Therefore, it is noteworthy that President-elect Donald Trump wants Robert F. Kennedy Jr., a leading critic of childhood vaccination, to be secretary of Health and Human Services.

The Conversation

Merck Reveals Mixed Data From Keytruda/Lynparza Regime In Ovarian Cancer

Merck's ovarian cancer trial met its primary endpoint, while lymphoma trial data set the Phase 3 dose for zilovertamab vedotin at 1.75 mg/kg.

Benzinga

How Is Merck's Stock Performance Compared to Other Pharmaceuticals Stocks?

Merck has underperformed the pharmaceuticals industry over the past year, but analysts are highly optimistic about the stock’s prospects.

Barchart

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Merck & Co Unusual Options Activity For December 02

Deep-pocketed investors have adopted a bearish approach towards Merck Co (NYSE:MRK), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in MRK usually suggests something big is…

Benzinga

Merck's WINREVAIR Achieves Results in PAH Study, Trial Ends Early on Efficacy

Merck (NYSE:MRK), known as MSD outside of the United States and Canada, announced today positive topline results from the Phase 3 ZENITH study evaluating WINREVAIR (sotatercept-csrk) in adults with pulmonary arterial

Barchart

Merck & Co. Stock: Is Wall Street Bullish or Bearish?

Despite Merck & Co.’s underperformance relative to the broader market over the past year, Wall Street analysts remain bullish about the stock’s prospects.

Fortune

We led some of America’s largest companies. Here’s why we are voting for Harris, not Trump

'We fear a second Trump term would be bad for business and the U.S. economy.'

Get all your
news in one place.

100's of premium titles.
One news app.

Kiplinger

Seven Stocks I Have Faith In

These companies have faced setbacks, but I'm confident their stock prices will flourish once again.

Fortune

Pneumonia can be a deadly complication of COVID, the flu, and RSV: What to know about pneumococcal vaccination

More than 41,000 people in the U.S. died of pneumonia in 2022, according to the CDC.

Fortune

How Merck leveled up its cybersecurity strategy since the NotPetya cyberattack that led to a $1.4 billion dispute

"It is integrated into everything that we do," says Merck's chief information and digital officer Dave Williams.

Barchart

Here's What to Expect From Merck & Co.'s Next Earnings Report

Merck & Co. is projected to report its third-quarter earnings result at the end of this month, and analysts expect a double-digit profit dip.

The Conversation

Pharma company funding for patient advocacy groups needs to be transparent

Patient groups should be playing a central role in Canada’s health-care system, advocating for their members by promoting the visibility of their conditions, pushing for more rapid and accurate diagnoses and lobbying for the introduction and funding of new treatments and drugs that may help relieve their members’ symptoms and…

The Conversation

Ozempic, Wegovy, Rybelsus: Are we losing sight of overall health? Here’s what the science says

The craze for new drugs in the GLP-1 (Glucagon-like peptide 1) and GIP (Gastric inhibitory polypeptide) analogue class, better known under the trade names Ozempic and Wegovy, is remarkable, but it’s not totally unprecedented in the history of pharmaceutical blockbusters.

International Business Times

Eighty-eight Corporate Leaders Endorse Harris For Continued 'Strength' Of Democracy, Economy

Letter signers include Yelp, Snap and Box CEOs, media empire heir James Murdoch, former CEOs of PepsiCo, Lyft and Merck

1 … 4 5 6 7

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.